Last reviewed · How we verify
EVO100
EVO100 is a vaginal contraceptive film that provides non-hormonal contraception through a spermicidal mechanism.
EVO100 is a vaginal contraceptive film that provides non-hormonal contraception through a spermicidal mechanism. Used for Contraception in women of reproductive age.
At a glance
| Generic name | EVO100 |
|---|---|
| Sponsor | Evofem Inc. |
| Drug class | Spermicide |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | Phase 3 |
Mechanism of action
EVO100 is a water-soluble vaginal film containing a spermicide that dissolves in vaginal fluid to create a contraceptive barrier. The film is designed to be inserted vaginally before intercourse and works by immobilizing and inactivating sperm, preventing fertilization. It offers a hormone-free contraceptive option for women seeking non-systemic birth control.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Vaginal irritation
- Genital discomfort
- Allergic reaction
Key clinical trials
- Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (PHASE3)
- Phase 2B/3 Double-blinded Placebo-controlled (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVO100 CI brief — competitive landscape report
- EVO100 updates RSS · CI watch RSS
- Evofem Inc. portfolio CI